International Journal of Hematology and Oncology
2025, Vol 35, Num 1 Page(s): 179-181
REPORTS FROM FOURTIETH AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO MEETING): BISPHOSPHONATE USE IN THE ADJUVANT TREATMENT OF BREAST CANCER
KADRİ ALTUNDAĞ1, BANU ARUN1
The University of Texas, M.D. Anderson Cancer Center, Breast Medical Oncology, Houston, Texas, USA
Bisphosphonates have beneficial effects on bone metastases. The bisphosphonates are expected to reduce or prevent the incidence of bone metastases by inhibiting tumor-induced osteoclastic resorption of bone when they are used as an adjuvant treatment of breast cancer. We summarize four abstracts about the adjuvant use of bisphosphonates in breast cancer patients presented in fourtieth ASCO meeting 2004.
KADRİ ALTUNDAĞ1, BANU ARUN1
The University of Texas, M.D. Anderson Cancer Center, Breast Medical Oncology, Houston, Texas, USA
Bisphosphonates have beneficial effects on bone metastases. The bisphosphonates are expected to reduce or prevent the incidence of bone metastases by inhibiting tumor-induced osteoclastic resorption of bone when they are used as an adjuvant treatment of breast cancer. We summarize four abstracts about the adjuvant use of bisphosphonates in breast cancer patients presented in fourtieth ASCO meeting 2004.